Contact us


Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer

For more information, please visit

Patient Population Investigational Product(s) Phase Status
Advanced/Metastatic HER2-Positive Breast Cancer MM-302 II Open and Accruing